Pharamaceutical Industries

Unichem Laboratories share price surged up to 4.1 5 per cent at Rs 671.55 per share on the BSE in Monday's intraday trade

Brokerages expect aggregate sales growth of 11 per cent, and 21 per cent earnings growth during this period

The domestic pharmaceutical industry expects another year of sustained growth in 2024 amid various challenges, including maintaining quality standards, while moving from volume to value leadership. The industry, known for catering to global markets with affordable generic products, expects to further leverage collaborative efforts, invest in Research & Development (R&D) and uphold quality standards to meet the evolving healthcare needs. "The convergence of policy thrust, and India's entrepreneurial vigour will propel the sector's growth and ensure a consistent supply of quality-assured affordable medicines for patients, both in India and globally," Indian Pharmaceutical Alliance (IPA) Secretary General Sudarshan Jain told PTI. IPA comprises top domestic pharmaceutical companies, including Sun Pharma, Dr Reddy's Laboratories, Aurobindo Pharma, Cipla, Lupin and Glenmark. Jain said that this year, the government announced various policy initiatives like the Promotion of Research .

Torrent Pharmaceuticals Ltd on Tuesday said the US health regulator has issued Form 483 with five procedural observations after inspecting its oral manufacturing facility situated at Bileshwarpura in Gujarat. As per the US Food and Drug Administration (USFDA), Form 483 is issued to a firm's management at the conclusion of an inspection when the investigator has observed any conditions that may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts. The USFDA conducted a pre-approval Inspection at the company's oral manufacturing facility situated in Bileshwarpura, Gujarat from December 5 to 11, 2023, Torrent Pharma said in a regulatory filing. "At the end of the inspection, the company was issued a Form 483 with five procedural observations. There was no observation related to data integrity reported,"it added. The company also said, "we will respond to the USFDA within the prescribed time frame and will work in close collaboration with the agency to ...

South Africa, Colombia and other countries that lost out in the global race for coronavirus vaccines are taking a more combative approach towards drugmakers and pushing back on policies that deny cheap treatment to millions of people with tuberculosis and HIV. Experts see it as a shift in how such countries deal with pharmaceutical behemoths and say it could trigger more efforts to make lifesaving medicines more widely available. In the COVID-19 pandemic, rich countries bought most of the world's vaccines early, leaving few shots for poor countries and creating a disparity the World Health Organization called a catastrophic moral failure. Now, poorer countries are trying to become more self-reliant because they've realized after COVID they can't count on anyone else, said Brook Baker, who studies treatment-access issues at Northeastern University. One of the targets is a drug, bedaquiline, that is used for treating people with drug-resistant versions of tuberculosis. The pills are

The company has secured marketing authorisation for bortezomib cisplatin, doxorubicin, docetaxel, flurouracil and paclitaxel from the Philippines.

Drugs in the National List of Essential Medicines contribute 17% of revenue: ICRA

The extension applies to both Small Scale Industries (SSI) and non-SSI manufactured drugs

The new rule highlights how governments are reassessing their reliance on India's $42 billion pharmaceutical industry since the contamination came to light last year

The Cameroonian authorities are still investigating the cause of the outbreak and plan to test the Naturcold samples connected to the deaths, Filbert said in a text message on June 5

Dr Reddy's Laboratories Ltd on Friday announced the launch of Regadenoson injection, used as an agent in the imaging of heart muscle to check blood flow, in the US market. Regadenoson injection is supplied as single-dose pre-filled syringes, 0.4mg/5ml (0.08 mg/ml). It is a generic therapeutic equivalent of Lexiscan injection, approved by US Food and Drug Administration (USFDA), Dr Reddy's said in a regulatory filing. The injection is a pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI) in patients unable to undergo adequate exercise stress. In a separate filing, Dr Reddy's said it has issued a Form 483 with one observation by the USFDA after a routine GMP inspection at its API manufacturing facility (CTO 1) in Bollaram, Hyderabad. "The inspection was conducted from May 1, 2023 to May 5, 2023. We have been issued a Form 483 with one observation, which we will address within the stipulated timeline," the company said. As per USFDA, Form 483 is issued to a

Specialty chemicals company Aether Industries on Thursday said it has signed an initial pact with the Gujarat government to set up new manufacturing plants at its Panoli Site with an investment of around Rs 1,000 crore. The company has signed a Memorandum of Understanding (MoU) with the Gujarat government to this effect, Aether Industries said in a statement. With an indicated investment of Rs 1,000 crore, generating future employment for more than 1,000 people, the company aims to commission the plants by the year 2025, the statement added. In the recent past, the company had purchased 1,25,000 sq. plots at Panoli GIDC, in Bharuch district. The company aims to utilise the Panoli plots in an efficient manner to manufacture a variety of products for the first time in India. Surat-based Aether produces advanced intermediates and specialty chemicals. The products find application in the pharmaceutical, agrochemical, material science, coating, high-performance photography, additive,

Dr Reddy's Laboratories is recalling over 4,000 bottles of a generic drug in the US due to a packaging error. The Hyderabad-based drug major is recalling 4,320 bottles of Tacrolimus Capsules which are used to prevent the body from rejecting a transplanted organ. New Jersey-based Dr Reddy's Laboratories Inc, a unit of the company, is recalling the affected lot due to "Presence of one Tacrolimus 1 mg capsule co-mingled in a bottle containing and labeled as Tacrolimus 0.5 mg capsules," USFDA said in its latest Enforcement Report. The affected lot was produced at the company's Bachupally-based manufacturing plant and marketed in the US by its American arm. Dr Reddy's initiated the Class II nationwide recall on February 8 this year. As per USFDA, a Class II recall is initiated in a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remot

Drug major Sun Pharma on Monday said it has completed the acquisition of US-based Concert Pharmaceuticals. In January, the Mumbai-based company inked a pact to acquire Concert in a USD 576 million deal. The drug major has successfully completed the acquisition of Concert Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company that is developing deuruxolitinib for the potential treatment of adult patients with moderate to severe alopecia areata, Sun Pharma said in a regulatory filing. "We are excited to add deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to our growing global dermatology portfolio and expand our presence in the Boston biotech hub," Sun Pharma North America CEO Abhay Gandhi said. By bringing together Concert's talented team with Sun Pharma's global reach and commercial capabilities, this acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patien

A Haryana court has sentenced to two-and-a-half years in jail two executives of a pharmaceutical company, which was recently under the scanner for alleged cough syrup related deaths in Gambia, in another case of export of sub-standard drugs to Vietnam nearly a decade ago. Additional Sessions Judge, Sonipat, Sanjeev Arya, sentenced Naresh Kumar Goel, Director of Maiden Pharmaceuticals, and Mahender Kumar Sharma, Technical Director, to jail and also imposed a fine of Rs one lakh each. The complainant, a drug inspector of the Central Drugs Standard Control Organisation (CDSCO), North Zone, Ghaziabad, had inspected the manufacturing premises of the company here to investigate the matter regarding the export of medical products from India to Vietnam in 2014. A sample of drugs was taken by the complainant during the investigation for testing and analysis. One portion of the sample was sent to Government Analyst, for a test at Regional Drugs Testing Laboratory Chandigarh in March 2014. Af

The government is taking steps to produce "high value pharmaceuticals" in the country to reduce import dependency for such critical articles, Union Minister Mansukh Mandaviya said on Tuesday. Manufacturing of components of high-end medical devices in the country will be another big step in moving towards self reliance, the Union Minister for Chemicals and Fertilisers noted. "Working on the vision of reducing import dependency through indigenous production, the government is focussing on production of high value pharmaceuticals and high-end medical devices," he said. Mandaviya said the Department of Pharmaceuticals (DoP) has released the first tranche of incentives under the Product Linked Incentive (PLI) scheme of pharmaceuticals amounting to Rs 166 crore to four selected applicants. Under the Atmanirbharta initiative of the government, DoP launched the PLI scheme for pharmaceuticals in 2021. The financial outlay under this PLI scheme is Rs 15,000 crore over a period of six years.

India's Laurus Labs Ltd reported a 32.1% rise in third-quarter profit on Monday, boosted by strong demand in its businesses that make chemicals and other ingredients used in medicines

The Mumbai-based drug maker's profit rose to 1.05 billion rupees ($12.86 million) in the three months ended Dec. 31, from 1.04 billion rupees a year ago

Will fund transaction from internal accruals

Govt finalises the draft notification issued in June